hrcak mascot   Srce   HID

Acta Pharmaceutica, Vol.67 No.2 Lipanj 2017.

Izvorni znanstveni članak
DOI: 10.1515/acph-2017-0016

Real-practice thromboprophylaxis in atrial fibrillation

PAOLA DEAMBROSIS ; Department of Pharmaceutical and Pharmacological Science, University of Padua, Largo Egidio Meneghetti 2, 35131, Padua, Italy; Local Health Authority n.9 of Treviso, Pharmaceutical Service, Piazza Ospedale 1, 31100, Treviso, Italy
ALESSANDRA BETTIOL ; Department of Pharmaceutical and Pharmacological Science, University of Padua, Largo Egidio Meneghetti 2, 35131, Padua, Italy
JENNY BOLCATO ; Local Health Authority n.9 of Treviso, Pharmaceutical Service, Piazza Ospedale 1, 31100, Treviso, Italy
ROBERTA PIROLO ; Local Health Authority n.9 of Treviso, Pharmaceutical Service, Piazza Ospedale 1, 31100, Treviso, Italy
GIULIA FRANCHIN ; Local Health Authority n.9 of Treviso, Pharmaceutical Service, Piazza Ospedale 1, 31100, Treviso, Italy
SAKIS THEMISTOCLAKIS ; Local Health Authority n.12 of Venezia, Hospital Unit of Electrophysiology and Electrostimulation Dell’Angelo Hospital, Via Paccagnella 11, 30174, Mestre, Italy
MICHELE PELLIZZARI ; Veneto Region, Regional Epidemiological Centre, Passaggio Gaudenzio 1, 35131, Padova, Italy
ALESSANDRO CHINELLATO ; Local Health Authority n.9 of Treviso, Pharmaceutical Service, Piazza Ospedale 1, 31100, Treviso, Italy
PIETRO GIUSTI ; Department of Pharmaceutical and Pharmacological Science, University of Padua, Largo Egidio Meneghetti 2, 35131, Padua, Italy

Puni tekst: engleski, pdf (540 KB) str. 227-236 preuzimanja: 32* citiraj
APA
DEAMBROSIS, P., BETTIOL, A., BOLCATO, J., PIROLO, R., FRANCHIN, G., THEMISTOCLAKIS, S., PELLIZZARI, M., CHINELLATO, A., GIUSTI, P. (2017). Real-practice thromboprophylaxis in atrial fibrillation. Acta Pharmaceutica, 67(2). doi:10.1515/acph-2017-0016

Sažetak
This retrospective observational study was based on databases of the Local Health Authority of Treviso, Italy. It evaluated the prevalence and the effectiveness of oral anticoagulation treatment (OAT) for the management of non-valvular atrial fibrillation (NVAF) in everyday clinical practice.
Out of 6,138 NVAF patients, only 3,024 received vitamin K antagonists (VKA). Potential barriers decreasing the probability of being treated with VKA were female sex, older age, antiplatelet treatment and a history of bleeding. In addition, VKA-treatment was not in line with current ESC and AIAC guidelines, since the patients at high or low risk of stroke were under- or over-treated, resp. Among VKA-treated patients, 73 % of subjects were not targeted for anticoagulation. OAT showed to be effective in reducing stroke risk. However, stroke events were also significantly influenced by previous stroke or transient ischemic attacks (hazard ratio, HR = 2.99, p < 0.001) and by previous bleeding events (HR = 1.60, p < 0.001).

Ključne riječi
atrial fibrillation; thromboprophylaxis; real-practice; vitamin K antagonists; stroke risk

Hrčak ID: 173059

URI
http://hrcak.srce.hr/173059

Posjeta: 69 *